Trial reportCNS oncology2019
A feasibility study of the Nativis Voyager
Trial report in CNS oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma.CNS oncology · 2023Trial
- Neuromodulation in Neuro-Oncology: A Scoping Review.Journal of personalized medicine · 2026Review
- Tumor-Treating Fields and Related Treatments in the Management of Pediatric Brain Tumors.Current oncology (Toronto, Ont.) · 2025Review
- Low-frequency magnetic field therapy for glioblastoma: Current advances, mechanisms, challenges and future perspectives.Journal of advanced research · 2025Review
- Evaluation of the EMulate Therapeutics Voyager's ultra-low radiofrequency energy in murine model of glioblastoma.Bioelectronic medicine · 2024Article
- Welcome to Volume 9 ofCNS oncology · 2020Article
- Article
- How far will the VoyagerCNS oncology · 2019Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimEvaluation of the Nativis Voyager MATERIALS &
methodsA total of 15 patients with rGBM were treated with one of two Voyager ultra-low radio frequency energy cognates: A1A or A2HU. Safety and clinical utility were assessed every 2-4 months.
resultsMedian overall survival was 8.04 months in the A1A arm and 6.89 months in the A2HU arm. No serious adverse events associated with Voyager were reported. No clinically relevant trends were noted in clinical laboratory parameters or physical exams.
conclusionThe data suggest that the Voyager is safe and feasible for the treatment of rGBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.